Hikma Pharmaceuticals Acquires Custopharm from Water Street Healthcare Partners
September 27, 2021
Hikma Pharmaceuticals has agreed to acquire Custopharm Inc., a US-based generic sterile injectables company, from Water Street Healthcare Partners for an initial $375 million plus up to $50 million in contingent consideration. The acquisition adds Custopharm's 13 approved products, R&D capabilities and pipeline to Hikma's injectables franchise and is expected to be accretive to Hikma's Injectables operating margin.
- Buyers
- Hikma Pharmaceuticals PLC
- Targets
- Custopharm Inc.
- Sellers
- Water Street Healthcare Partners
- Industry
- Pharmaceuticals
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Water Street Healthcare Partners Acquires Pillr Health from Renovus Capital Partners
January 20, 2026
Healthcare Services
Renovus Capital Partners has sold its portfolio company Pillr Health, a technology-enabled pharmacy optimization platform, to Water Street Healthcare Partners. Pillr Health provides software and tech-enabled services to help healthcare providers manage pharmacy operations, ensure 340B compliance, and improve financial and operational outcomes.
-
Jabil Acquires Pharmaceutics International (Pii)
February 6, 2025
Pharmaceuticals
Jabil has acquired Pharmaceutics International (Pii), a Hunt Valley, Maryland-based contract development and manufacturing organization (CDMO) that provides aseptic filling, lyophilization and oral solid dose manufacturing. The all-cash transaction represents an exit for a consortium led by Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital and Pharmascience Inc., and brings Pii’s ~300+ employees and four-site campus into Jabil’s Pharmaceutical Solutions offering to expand its drug development and manufacturing capabilities.
-
Noramco Acquires Cambrex Drug Product Business Unit (Halo Pharmaceuticals)
November 2, 2023
Pharmaceuticals
Noramco has completed the acquisition of the Cambrex Drug Product Business Unit (previously Halo Pharmaceuticals), adding drug product formulation development, clinical and commercial manufacturing, and packaging capabilities from sites in Mirabel, Québec and Whippany, New Jersey. The purchase expands Noramco's service offering beyond APIs, brings nearly 400 employees into the Noramco group, and represents Cambrex's strategic divestiture to focus on its drug substance and analytical testing businesses.
-
Water Street Healthcare Partners Invests in Avantik
February 15, 2023
Healthcare Services
Avantik has partnered with Water Street Healthcare Partners, which has committed growth capital and sector experience to support Avantik's next phase of expansion. The investment will fund organic initiatives and acquisitions to expand Avantik's consumables, equipment and maintenance services; Mark Zacur was appointed CEO to lead the growth plan.
-
H.I.G. Capital Makes Strategic Equity Investment in Rising Pharmaceuticals
December 13, 2021
Pharmaceuticals
An affiliate of H.I.G. Capital has made a strategic equity investment in Rising Pharma Holdings and Casper Pharma (together, Rising Pharmaceuticals) to support the company's growth, M&A activity and new product launches. Rising Pharmaceuticals is an asset-light developer and marketer of generic and specialty pharmaceuticals based in New Jersey with a diversified portfolio of over 125 products and a network of 23+ CMO/CDO partners.
-
Pouschine Cook Leads Investment in Curexa Pharmacy
December 4, 2021
Healthcare Services
Pouschine Cook Capital Management led a growth investment in Curexa Pharmacy, a PCAB-accredited 503A compounding pharmacy that partners with direct-to-consumer telemedicine brands. Institutional co-investors included ORIX Corporation USA’s Private Equity Solutions group and Hexagon; First Horizon Bank provided senior credit facilities and management completed a meaningful rollover to support continued scaling of Curexa’s digital and pharmacy infrastructure.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.